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Background: While 68Ga-PSMA PET-MRI might be superior to PET-CT with regard to soft tissue assessment in
prostate cancer evaluation, it is also known to potentially introduce additional PET image artefacts. Therefore, the
impact of PET acquisition duration and attenuation data on artefact occurrence, lesion detectability, and
quantification was investigated.
To this end, whole-body PET list mode data from 12 patients with prostate cancer were acquired 1 h after injection
of 2 MBq/kg [68Ga]HBED-CC-PSMA on a hybrid PET-MRI system. List mode data were further transformed into
data sets representing 300, 180, 90, and 30 s acquisition duration per bed position. Standard attenuation and
scatter corrections were performed based on MRI-derived attenuation maps, complemented by emission-based
attenuation data in areas not covered by MRI. A total of 288 image data sets were reconstructed with varying
acquisition durations for emission and attenuation data with and without scatter and prompt gamma correction,
and further analysed regarding image quality and diagnostic performance.
Results: Decreased PET acquisition durations resulted in a significantly increased incidence of halo artefacts around
kidneys and bladder, decreased lesion detectability and lower SUV as well as markedly lower arm attenuation
values: Halo artefacts were present in 5 out of 12 cases at 300-s duration, in 6 at 180 s, in 10 at 90 s, and in 11
cases at 30 s. Using attenuation data of the 300 s scans restored artefact occurrence to the original 300-s level.
Prompt gamma correction only led to small improvements in terms of artefact occurrence and size. Of the 141
detected lesions in the 300-s images one lesion was not detected at 180 s, 28 at 90 s, and 64 at 30 s. Using the
300-s attenuation map decreased non-detectability of lesions to zero at 180 s, 9 at 90 s, and 52 at 30 s. Attenuation
maps at 90 and 30 s demonstrated markedly lower mean arm attenuation values (0.002 cm-1) than those at 300 s
(0.084 cm-1), and 180 s (0.062 cm-1).
Conclusions: Short acquisition durations of less than 3 minutes per bed position result in unacceptable image
artefacts and decreased diagnostic performance in current whole-body 68Ga-PSMA PET-MRI and should be avoided.
Increased image noise and imperfections in generated attenuation maps were identified as a paramount cause for
image degradation.
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Cells of prostate cancer, the most frequent cancer in
men worldwide [1], usually show an overexpression of
the membrane-bound metallopeptidase prostate specific
membrane antigen (PSMA) [2]. Several radioactively-
labelled PSMA ligands have been developed for prostate
cancer imaging with positron emission tomography
(PET) and single photon emission computed tomog-
raphy (SPECT) [3–5]. Of these, [68Ga]-PSMA-HBED-CC
(68Ga-PSMA) has found the most widespread applica-
tion for use with PET-CT (PET combined with computer
tomography). There is mounting evidence that 68Ga-
PSMA PET-CT could become a new standard for imaging
of prostate cancer and its metastases [6–8].
The recently introduced integrated PET-MRI systems
promise further advances in multimodal imaging of
prostate cancer by providing better soft tissue contrast,
additional parameters such as diffusion and perfusion,
and a reduced radiation exposure compared to PET-CT.
Consequently, a current study suggests a superiority of
68Ga-PSMA PET-MRI for the detection of prostate can-
cer lesions compared to PET-CT [9].
It has to be noted, however, that 68Ga-PSMA PET-
MRI images can exhibit areas of artificially reduced ap-
parent tracer uptake (also known as “halo artefacts”) in
the vicinity of “hot” structures with high tracer uptake
(especially kidneys and bladder) in scatter-corrected im-
ages [10–12]. Critically, tumour manifestations within
these areas might be non-detectable. Additional images,
reconstructed without scatter correction, may alleviate
this problem to a certain degree [12].
Further insight into the cause of these artefacts and
subsequent optimization of imaging protocols are war-
ranted as a consequence in order to minimise the ad-
verse effect on diagnostic accuracy. A recent study by
Lütje et al. investigated the influence of acquisition time
per bed position on the degree of halo artefacts for a
single-bed position (pelvis) and at delayed imaging time
points (3 h after injection) [13]. The results of this study
show a degradation of image quality with decreasing
PET acquisition duration and support an optimal scan
duration of 4 min per bed position.
Scatter correction algorithms rely on an accurate
attenuation map. Investigating the influence of the im-
plementation of attenuation correction on the aforemen-
tioned halo artefacts should help to provide valuable
insights into this problem. MR-based attenuation correc-
tion is not straightforward, since the image information
provided by MRI is not directly related to tissue density
with respect to ionizing radiation as in PET or CT. The
standard procedure implemented for the Siemens Bio-
graph mMR scanner (Siemens Healthineers, Erlangen,
Germany) is based on MR-based segmentation of differ-
ent tissue classes (air, lung, fat, water; ±bone for brainimaging) and voxel-wise application of typical attenu-
ation values. Besides known issues in bone attenuation
correction [14], attenuation maps of the arms of patients
represent a major challenge. Due to limited space in the
scanner bore and prolonged scanning durations, patients
are usually positioned with their arms beside their bod-
ies, while the standard procedure for PET-CT is scan-
ning with arms elevated over the head. The transverse
MRI field of view in the current implementation of the
Siemens mMR sequence for attenuation correction is
too small to completely include the arms in most cases
resulting in truncated attenuation maps [15]. The miss-
ing portion of the attenuation map is derived from the
PET emission data [16]; therefore, PET scan duration
could indirectly influence the quality of the attenuation
map and finally the quality of the reconstructed images.
Furthermore, it has been suggested that scattered
prompt gamma photons of 1077 keV emitted during a
fraction of decays of 68Ga may contribute to the occur-
rence of halo artefacts in 68Ga-PSMA PET-CT [17];
however, systematic investigations of this issue in PET-
MRI have not yet been conducted.
In this study, we therefore investigated the influence of
PET acquisition duration on the quality of both emission
as well as attenuation data in whole-body 68Ga-PSMA
PET-MRI obtained 1 h after tracer injection and how
this affects image artefacts, lesion detectability, and
quantification.
Methods
Patient data and preparation
All patients included into this study underwent PET-
MRI imaging with a clinical indication, from June to
September 2016. The clinically acquired PET and MRI
data were retrospectively analysed in accordance to local
institutional and ethical guidelines.
Data from twelve male patients (age: 65.3 ± 9.3 years,
body mass: 86.8 ± 9.1 kg) who were referred for 68Ga-
PSMA PET-MRI, either for initial staging of prostate
cancer (n = 3) or for restaging due to biochemical recur-
rence (n = 9), were included in this study. Approximately
2 MBq [68Ga]-PSMA-HBED-CC per kg body weight
(range: 144–198 MBq) were injected intravenously,
followed by a 20 ml saline flush, 65 ± 9 min (range: 54–
82 min) before the start of the PET scan. Patients were
told to void their bladder before the scan.
Data acquisition
All data were acquired on a combined PET-MRI sys-
tem capable of simultaneous PET and MRI acquisition
(Biograph mMR, Siemens Healthineers, Erlangen,
Germany; NUMARIS/4 software version B20P). Pa-
tients were positioned supine with arms lying next to
the body. Head/neck and body surface coils were used
Fig. 1 PET reconstructions performed in this study, combining
different emission, and attenuation data sets
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point Dixon sequence for MR-based attenuation cor-
rection. All voxels in the field of view were classified
into one of the four tissue compartments air, lung, fat,
and water in order to provide an attenuation map of
the volume covered by MRI. Subsequent PET imaging
covered the whole-body from the head to the knee
level, resulting in five to seven bed positions. For all
bed positions PET data were collected for 5 min in
“list mode” acquisition mode, in which individual
counts are saved for later sorting and image recon-
struction. During and after PET acquisition diagnostic,
MR imaging was performed; MRI data were only used
in this study to distinguish tumour lesions from
physiological activity, e.g., in the urogenital tract, by
consensus reading of two nuclear medicine and two
diagnostic radiology experts (one in each group board
certified with >15 years of clinical experience).
PET image reconstruction
All relevant acquisition data (PET list mode data, MR-
derived attenuation map) were transferred to a separate
workstation for offline data processing. Whole-body list
mode PET data were reconstructed using the offline
sorting and reconstruction programs included in the e7
toolbox (Siemens Healthineers, Erlangen, Germany; ver-
sion VA20). To this end, every list mode file was first
binned into sinograms. In order to investigate different
acquisition durations, several sinogram sets were con-
structed by first using all data from the 300-s scan, then
with decreasing statistics by only taking into account the
first 180, 90, and 30 s of list mode data, respectively, as
described previously by Armstrong et al. [18]. Attenu-
ation maps (AM) were generated from MR data (stand-
ard Dixon sequence-based segmentation of air, lungs,
fat-, and water-like tissue). Between shoulder and pelvis,
where MRI coverage of the arms is incomplete, maps
were automatically complemented by attenuation data
derived from the PET emission data using the maximum
likelihood reconstruction of activity and attenuation
(MLAA) algorithm [16]. Since the sinogram data are
used for both the emission data and for MLAA-based at-
tenuation correction (AC), and hence also for scatter
correction (SC), several different combinations of emis-
sion/AM timings are possible.
For each patient the following ten image data sets
were reconstructed from these sinogram data (Fig. 1):
(1) Reference: sinograms obtained from the full 300 s
were used for both emission data and MLAA-based
attenuation and scatter correction (one data set);
(2) Emission and AM reduced (“native AM”): sinogram
data with reduced acquisition duration were used in
parallel for the emission data and for MLAA-basedattenuation and scatter correction (three data sets
for 180, 90, 30 s);
(3) Emission-only reduced (“300-s AM”): sinograms
with reduced time duration were only used for the
emission data while the complete 300-s sinogram
data (as representing arguably the best estimate of
arm attenuation) were used for MLAA-based at-
tenuation and scatter correction (three data sets);
(4) AM-only reduced (“300-s emission”): sinograms
with reduced time duration were only used for
MLAA-based attenuation and scatter correction
while the complete 300-s sinogram data were used
for the emission data (three data sets).
The image data under (2) reflect the clinical situation
with reduced acquisition times, while the image data
under (3) and (4) provide insight into the relative contri-
bution of the emission data and the attenuation maps.
All PET data were calibrated, normalised, and corrected
for attenuation, random and scattered coincidences. Dis-
tributions of scattered events for scatter correction were
calculated using the standard e7 scatter correction
algorithm based on the respective emission data and the
determined MLAA-based attenuation maps. Scaling of
these distributions was performed by tail-fitting to the
measured emission data outside the apparent body of
the patient as determined from the attenuation map
(“relative scaling”).
In order to determine the influence of prompt gamma
photons on halo artefact occurrence, reference and na-
tive AM data were additionally reconstructed with the
prompt gamma correction (PGC) algorithm for 68Ga
implemented in the e7 tools which is currently not
available on the clinical PET-MRI system.
Whole-body image reconstructions were performed
using a standard ordinary Poisson ordered subsets
expectation maximization algorithm (OP-OSEM) with 3
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full-width-half-maximum was applied after reconstruc-
tion. Reconstructed PET images consisted of 344 × 344
voxels in the axial slices, each with dimensions of 2 ×
2 × 2 mm3.
For further testing of the assumption that additional
images reconstructed without scatter correction can alle-
viate some of the problems caused by the halo artefacts,
additional images with attenuation correction but with-
out scatter and prompt gamma correction were recon-
structed for all of the above scenarios. In total, 24 image
data sets per patient (288 altogether) were reconstructed
for subsequent analysis.
Image analysis
All PET images were analysed visually by two
experienced nuclear medicine professionals (physician
and physicist) with respect to the presence and location
of “halo artefacts” and with respect to the detectability
of tumour lesions. Additionally, tracer uptake in the
scatter-corrected images was quantified as maximum
standardized uptake values (SUVmax). Finally, the vol-
ume of the arms added to the MRI-derived attenuation
map by the emission-based MLAA algorithm was deter-
mined for every image data set in the pelvic bed pos-
ition, together with a typical attenuation value found in
a portion of the forearm added to the MRI-based attenu-
ation map by the MLAA method. All analyses were
undertaken by using the AMIDE image analysis software
(Version 1.0.1, amide.sourceforge.net).
Halo artefacts
Halo artefacts, presenting in the scatter-corrected im-
ages as apparently hypointense regions around the
kidneys and the bladder (i.e., the organs with a very
high tracer accumulation), were classified with respect
to location and quantity: 0: no visible artefact; 1: halo
around either kidneys or bladder; 2: halos around kid-
neys and bladder.
Tumour detectability
The detectability of PSMA-positive tumour lesions that
were visible in the reference images reconstructed using
300-s acquisition data were classified for all image data
sets with reduced count statistics (reduced for emission
data, attenuation correction or both, with and without
scatter correction) according to the following scheme: 0:
not detectable; 1: equivocal; 2: discernible; 3: clearly
visible. Since both image data sets, with and without
scatter correction (+SC and -SC), are available for
image interpretation in clinical routine, a composite
score was calculated as the maximum score from
both image data sets.Standardized uptake values (SUV)
Maximum standardized uptake values (SUVmax) were
calculated for every tumour lesion with a detectability
score >0 in the scatter-corrected images at all scan dura-
tions as follows:
SUVmax ¼ cmax⋅dcf ⋅mA0 ;
with cmax denoting the maximum
68Ga-PSMA radio-
activity concentration in the respective lesion, m the
body mass of the patient, A0 the injected amount of
radioactivity at time of injection, and dcf the decay cor-
rection factor between the time of tracer injection and
the start time of the PET scan.
As prompt gamma correction is currently not available
for clinical reconstructions, tumour detectability and
SUV determination was not performed on the images
reconstructed using the prompt gamma correction algo-
rithm of the e7 tools.
In order to assess possible relations between tracer
uptake and halo occurrence, SUVmean of the brightest
kidney and of the bladder as defined by a volume of
interest based on 50% of SUVmax were determined
and correlated to halo occurrence around the respect-
ive organ. This analysis was performed on the original
PET data set comprising 300-s acquisition duration
per bed position.Attenuation map alterations caused by MLAA
The pelvic bed positions were analysed to assess the
influence of decreasing emission data statistics on
MLAA-based arm completion in the computed at-
tenuation maps. This was done by determining the
total volume of arm voxels added to the Dixon
sequence-derived attenuation map by MLAA with at-
tenuation values higher than 0.005 cm-1. Additionally,
the mean attenuation value of a representative spher-
ical volume-of-interest (VOI) in the right forearm
(diameter: 20 mm) was determined.Statistics
Data are presented as mean ± standard deviation. Signifi-
cant differences were tested by paired two-tailed Wil-
coxon signed rank tests (for detectability scores and
SUV) using the statistical toolbox in MATLAB (version
2013b; MathWorks, Natick, USA). A Holm-Bonferroni
correction for pairwise comparisons was applied to com-
pensate for the growth of the family-wise error rate
when performing multiple tests. The family-wise error
rate was set to 0.05.
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Finally, we present a typical case to highlight the clinical
impact of different acquisition durations on 68Ga-PSMA
PET image quality in PET-MRI.Results
Halo artefacts
In native scatter- and attenuation-corrected images, dis-
tinct halo artefacts around the kidneys and/or bladder
were seen in five out of 12 cases (41.7%) for 300-s im-
ages, in 6 for 180 s (50.0%), in 10 for 90 s (83.3%), and
in 11 cases for 30-s images (91.7%; Table 1, Fig. 2,
Additional file 1), indicating a marked increase in the
number of halo artefacts with decreasing count statistics.
Mean halo scores (± standard deviation) amounted to
0.50 ± 0.67 for 300 s, 0.67 ± 0.78 for 180 s, 1.67 ± 0.78 for
90 s, and 1.67 ± 0.65 for 30 s. Differences between 300 s
and 90 s/30 s as well as differences between 180 s and
90 s/30 s were significant. Interestingly, when using the
attenuation map derived from 300-s emission data for
AC and SC, no such increase in halo artefacts with re-
duction of acquisition duration was observed, and halo
scores remained on the level of 300-s emission data
(Fig. 2). In contrast, emission data obtained from the full
300-s data set reconstructed with attenuation maps of
decreased scanning durations again resulted in increas-
ing artefact numbers (Fig. 3), demonstrating the pro-
found effect of MLAA-based arm completion on halo
artefact appearance. Native images reconstructed using
prompt gamma correction had mean halo scores of 0.50
± 0.67 for 300 s, 0.67 ± 0.78 for 180 s, 1.67 ± 0.78 for
90 s (identical to the scores of the images reconstructed
without PGC), and 1.25 ± 0.75 for 30 s, demonstrating a
limited effect of this correction on halo occurrence, al-
though artefact sizes seemed to be slightly smaller in the
images corrected for prompt gammas (Fig. 3).Lesion detectability
Altogether, 141 lesions were identified in 12 patients
(range: 0–35 lesions per patient): 98 bone metastases, 33
lymph node metastases, 8 lesions of the prostate gland
or seminal vesicle and 2 liver metastases. All lesions
were located in bed positions where MLAA-basedTable 1 Number and locations of halo artefacts in a total of 12 who
Native AM 300-s AM
Acquisition duration (s) Kidney halo Bladder halo Kidney halo Bla
300 4 2 4 2
180 6 2 4 2
90 10 10 4 2
30 11 9 3 2completion of the attenuation maps were performed
(i.e., from shoulder to pelvic regions).
In the scatter-corrected images all except one of the
unequivocally detectable lesions (score value ≥2) in the
reference 300-s images were also detected in the native
180-s images (0.7%); however, 28 lesions were undetect-
able in 90-s images (19.9%), and 64 in 30-s images
(45.4%; Fig. 4, Additional file 2). When using the 300-s
attenuation map for AC and SC, only 9 lesions were
missed in the 90-s images (6.4%), and 52 in the 30-s
images (36.9%).
In the images reconstructed without scatter correction,
all lesions were detectable in the 300-s data set. How-
ever, three lesions were undetectable in the 180-s images
(2.1%), 22 in 90-s (15.6%) and 66 in 30-s images (46.8%).
Both data sets, with and without scatter correction (+SC
and -SC) taken together, yielded zero undetectable
lesions when going from 300-s to 180-s but 16 undetect-
able lesions in the 90-s (11.3%) and 54 in the 30-s
images (38.3%) in the case of native attenuation maps,
and 9 undetectable lesions in the 90-s (6.4%) and 49 in
the 30-s images (34.8%) in the case of using the 300-s
attenuation map (Fig. 4).
The mean detectability scores in the scatter-corrected
images amounted to 2.95 ± 0.22 for 300-s images, 2.88 ±
0.35 for 180 s, 2.33 ± 1.09 for 90 s, and 1.67 ± 1.26 for
30-s images. Every difference was found to be significant.
Using the 300-s attenuation map for AC and SC,
detectability scores improved to 2.89 ± 0.31 for 180 s,
2.67 ± 0.62 for 90 s and 1.88 ± 1.15 for 30-s images, re-
spectively. Only the latter two values were found to be
significantly different from the original value. This im-
provement was caused by halo artefact suppression, thus
lesions previously masked by halos became detectable.
The residual loss in detectability was most likely caused
by increased image noise.
Mean detectability scores in the non-scatter-corrected
images amounted to 2.91 ± 0.29 for 300-s images, 2.85 ±
0.41 for 180 s, 2.47 ± 0.82 for 90 s and 1.60 ± 1.20 for 30-
s images; each score value was found to be significantly
different from the others. Both data sets with and with-
out scatter correction (+SC and -SC) taken together
yielded 2.96 ± 0.19 for 300-s images, 2.94 ± 0.25 for
180 s, 2.61 ± 0.74 for 90 s, and 1.84 ± 1.19 for 30-sle-body 68Ga-PSMA PET-MRI scans
300-s emission Native AM,
+PGC
dder halo Kidney halo Bladder halo Kidney halo Bladder halo
4 2 4 2
6 2 6 2
10 10 10 10
11 9 10 5
Fig. 2 Coronal slice of a whole-body PSMA-PET reconstructed with varying acquisition durations for both emission data and attenuation map
creation (“native AM”, upper row), and varying acquisition durations only for the emission data while the attenuation map was derived from the
full 300-s data set (“300-s AM”, lower row). The red arrow marks a lymph node metastasis, clearly visible in the high-statistics 300- and 180-s
images but undetectable in the 90 and 30-s scans using native AM
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± 0.25 for 180 s, 2.69 ± 0.61 for 90 s, and 1.91 ± 1.16 for
30-s images in the case of using the 300-s attenuation
map. All differences in detectability scores were found to
be significant in both cases, except the differences be-
tween 300 and 180 s.
Standardized uptake values (SUV)
The number of lesions with a detectability score >0 (at
least equivocally detectable) at all scan durations
amounted to 102. Among these, reduction of acquisition
duration from 300 to 180 or 90 s (for both emission dataand attenuation/scatter correction likewise) led to a sig-
nificant drop in SUVmax (17.6 ± 17.4 for 300s, 17.1 ± 17.4
for 180s, 15.9 ± 16.8 for 90-s images; Fig. 5, Additional
file 3). For 30-s images mean SUVmax was 17.0 ± 17.8, a
slight increase from the 90-s images. When using the
300-s attenuation map for AC and SC, the opposite ef-
fect was observed: Reduction in acquisition duration led
to an increase in mean SUVmax (17.6 ± 17.8 for 180 s,
17.8 ± 17.9 for 90 s, and 19.3 ± 19.3 for 30-s images).
No apparent relation was found between SUVmean of
either kidneys or bladder and halo artefact occurrence
(Fig. 6 and Additional file 4).
Fig. 3 Coronal slice of a whole-body PSMA-PET (identical to Fig. 2) reconstructed with the full 300-s emission data but with a decreasing count
statistics for attenuation map generation (“300-s emission”, upper row), and reconstructed with varying acquisition durations for both emission
data and attenuation map creation as well as prompt gamma correction (“native AM + PGC”, lower row). The lymph node again is not visible at
180 s but weakly reappears in the 30-s data sets
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Reduction of acquisition time showed a significant im-
pact on arm completion in the MLAA-based attenuation
map (Fig. 7 and Additional file 5). The volume of com-
pleted arms in the pelvic bed position decreased from
4648 ± 1180 mL for 300-s images to 4109 ± 1314 mL for
180 s and 1745 ± 688 mL for 90 s images. For the 30-s
images, the additional arm volume increased again to
2055 ± 375 mL. The mean VOI value of the arm attenu-
ation map dropped from 0.084 ± 0.004 cm-1 for 300-s
images to 0.062 ± 0.023 cm-1 for 180 s and 0.002 ±0.004 cm-1 for 90-s images (water attenuation value for
comparison: 0.096 cm-1). Further reduction to 30-s ac-
quisition time resulted in a mean value of 0.002 ±
0.003 cm-1.Case presentation
Figure 8 demonstrates the impact of different acquisition
durations in a clinical 68Ga-PSMA PET-MRI study of a
49-year-old patient (body mass: 79 kg; 159 MBq radio-
tracer; acquisition start 65 min post injection) who was
Fig. 4 Number of lesions and detectability scores of 141 PSMA-PET-positive lesions for different reconstruction types and acquisition durations
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prostate exam.
At 300-s acquisition duration scatter-corrected PET
showed intense tracer uptake of the entire left periph-
eral zone (SUVmax: 43.3) and a focal uptake in the
right peripheral zone (SUVmax: 9.1) of the prostate
gland, highly indicative for prostate cancer. Reduction
of acquisition time to 90 s resulted in effacement of
detectable tracer accumulation in the right peripheral
prostate gland due to the presence of large halo arte-
fact areas around the bladder.
Discussion
The aim of this study was to evaluate the interrela-
tion of PET acquisition time, attenuation correction,Fig. 5 Mean SUVmax for different PET acquisition durations and AM
settings. An asterisk denotes significant differenceshalo artefacts, and resulting lesion detectability in
whole-body 68Ga-PSMA PET-MRI.
Results from this study show that halo artefacts
around the kidneys and the urinary bladder, organs with
high radiotracer activity, are indeed a relevant issue in
68Ga-PSMA PET-MRI acquired with the clinical Sie-
mens mMR hybrid PET-MRI system, potentially ham-
pering lesion detectability and quantification. Halo
artefacts were found in approximately 40 to 90% of at-
tenuation- and scatter-corrected images, depending onFig. 6 Halo artefact occurrence and SUVmean of high-contrast organs
in the reference 300-s images
Fig. 7 Example of MLAA-derived arm attenuation completion at different acquisition durations (coronal slices, top row). The volume of completed
arms generally decreases with decreasing durations (bottom left). A similar trend is seen in the attenuation map values in a VOI inside the right
arm (20 mm diameter, bottom right)
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down to 30 s. A similar proportion of patient scans with
halo artefacts was previously reported by Afshar-
Oromieh et al. They found artefacts around the kidneys
in 11 and around the bladder in 15 out of 20 patients in
scans with durations of 300 s per bed position [9]. How-
ever, since image acquisition was performed after
completion of PET-CT and therefore much later than in
our study, results are not comparable head-to-head.
The above data show that reduction of acquisition
duration results in an increase in likelihood of haloFig. 8 Coronal pelvic slice of a 68Ga-PSMA PET-MRI study dissecting the pr
acquisition durations per bed position (300 vs. 90 s). Green arrows refer to
cancer, while the red arrow refers to a missed lesion due to extensive halo
the T1-weighted MR image. “bl”: urinary bladder; “ur”: ureterartefacts in our setup, especially with durations lower
than 180 s per bed position. In a recent publication by
Lütje et al. the effect of acquisition time on the occur-
rence of artefacts has been studied for a single-bed pos-
ition (pelvis) acquired in list mode approximately three
hours after injection of 68Ga-PSMA tracer in PET-MRI
[13]. Their results are largely in line with the results
obtained within this study. However, the study presented
here extends to whole-body acquisitions (instead of
single-bed position scans) and a 1-h post injection im-
aging time point. Most importantly, we also studiedostate gland, demonstrating loss of diagnostic accuracy at different PET
strong focal uptake in the prostate, highly suspicious for prostate
artefact occurrence at 90 s. Yellow arrows denote lesion locations on
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pendency of halo artefacts.
Since halo artefacts are not observed in images recon-
structed without scatter correction and also not fre-
quently encountered in PET from PET-CT [9],
inadequate scatter correction, which in turn relies on
the determined attenuation map, is a likely contributor
to these artefacts. In order to further investigate this
topic, we separated the effects of acquisition time reduc-
tion for emission data and for determination of the at-
tenuation map in parts of the arms using the MLAA
algorithm. Acquisition times were varied for one compo-
nent at a time while leaving the other unchanged at
300 s. Results revealed that a reduction of acquisition
time for the attenuation map resulted in more frequent
and more severe halo artefacts, whereas a sole reduction
of emission data statistics did not result in an increase of
halo artefacts. Naturally, image noise increased for im-
ages with lower count statistics. This demonstrates at
least one causative role of insufficient arm completion in
the MLAA attenuation maps in the emergence of halo
artefacts. In order to further investigate the role of
MLAA arm completion, we investigated differences in
the resulting attenuation map when varying the duration
of data acquisition. Indeed, the volume of added arm at-
tenuation not covered by the MR-derived attenuation
map varied significantly with acquisition duration. Fur-
thermore, the resulting density of the complemented
arms in the attenuation maps varied considerably be-
tween acquired data with different durations. In conclu-
sion, varying acquisition times per bed position not only
directly influence the emission data but also heavily
influence the attenuation map and further the scatter
correction, specifically the scaling of the determined
scatter distributions to scatter tails outside the assumed
body contours.
68Ga also emits prompt gamma photons of 1077 keV
in addition to positrons in a small amount of decays
(≈1.2%), therefore potentially contaminating emission
data when Compton-scattered prompt gamma photons
are detected in coincidence with annihilation photons
[19]. This contamination was shown to be at least in
part responsible for introducing halo artefacts in 68Ga-
PSMA PET-CT data, and dedicated correction methods
resulted in PET images of reduced halo artefacts [17].
Our study demonstrates that the situation in PET-MRI
seems to be different, as the positive impact of PGC was
rather limited in terms of artefact occurrence. Possibly
the influence of insufficient arm completion on halo
artefacts is more important than prompt gamma con-
tamination in PET-MRI, while prompt gamma contam-
ination becomes a dominating cause for artefacts in
PET-CT where CT-derived attenuation maps usually do
not show truncation effects.This is to our knowledge the first investigation of
underlying mechanisms of 68Ga-PSMA-related artefacts
in the Siemens Biograph mMR system for clinical
whole-body scanning. As has been shown before [13],
halo artefacts are clinically relevant as they may result in
the non-detection of tumour lesions. Our results con-
firm this observation. We investigated the detectability
of lesions and also their intensity. Lesions started to be
missed in relation to the full 300-s scans when acquisi-
tion times per bed position fell below 180 s. Since halo
artefacts do not appear in non-scatter-corrected images
it has been proposed to compensate by additionally
evaluating the non-scatter corrected images [13]. To test
whether this approach is sufficient to alleviate the prob-
lems of halo artefacts in clinical routine imaging we ana-
lysed the lesion detectability of scatter-corrected and
non-scatter-corrected images in various settings. For
scan durations of 300 and 180 s per bed position, no
relevant differences in lesion detectability were observed.
Further reduction to 90 or 30 s frames led to a missing
of lesions, even when analysing scatter-corrected and
uncorrected images together. This demonstrated that
analysing the non-scatter-corrected images cannot fully
compensate the detrimental effects of the insufficient at-
tenuation map at 90-s acquisition duration. It is a key
result from this study that scan durations to be used for
PET-MRI imaging cannot be taken from experience in
PET-CT. In recent publications on 68Ga-PSMA PET-CT,
acquisition times per bed position ranged from 5 min
[9] to 1.5 min [20–22], the latter being proven too short
for adequate imaging in PET-MRI in the settings of our
study.
In this study we also analysed the impact of acquisi-
tion duration on standardized uptake values. Earlier
studies using PET-CT have shown an increase of SUV-
max with decreasing scan time due to increasing noise
[23, 24]. We could also show this effect when recon-
structing the images with reduced emission data and the
full 300-s attenuation map. However, reconstructing the
images with reduced statistics also used for generation
of the attenuation map resulted in a drop of mean SUV-
max at clinically used acquisition durations of 180 and
90 s. This effect is most probably caused by the insuffi-
cient arm completion and the resulting emergence of
halo artefacts, overcompensating the effect of increasing
image noise.
Limitations
The results of this study strictly seem only valid for the
setup of this study with regard to the imaging device
(Siemens Biograph mMR), injected activity and delay be-
tween tracer injection and acquisition. However, since
these conditions are characteristic for clinical imaging,
the results should influence current PET-MRI imaging
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bed position.
If the injected activities were reduced or image acqui-
sition would be started later after tracer injection, similar
reductions in imaging accuracy as seen in this study
would be expected. 68Ga-PSMA activities as low as
~50 MBq, which were shown to be sufficient for PET-
CT imaging [25], might not suffice for current PET-MRI
imaging. Lütje et al. have found an optimal imaging time
of 4 min per bed position when imaging 3 h post-
injection. This suggested longer acquisition duration as
compared to ours is explainable by the later scanning
time and the single-bed position scans, and hence lower
sensitivity and count rates, and is thus in line with the
results of this study with imaging one hour post injec-
tion. Furthermore, previous studies have shown a benefit
on tumour-to-background ratios when postponing the
acquisition start to 3 h after injection in PET-CT [26].
However, keeping in mind the effect of reduced soft
tissue counts on the MLAA-based arm completion, this
might be uncertain in PET-MRI imaging and imaging
time will have to be longer to compensate for this effect.
Recently, novel PSMA ligands labelled with 18F instead
of 68Ga have been developed (e.g., [18F]DCFPyL,
[18F]PSMA-1007, and [18F]YC-88). It remains to be seen
if these tracers will suffer from similar problems in clin-
ical PET-MRI settings. However, one advantage besides
others is the fact that 18F is a pure positron emitter with-
out additional prompt gamma emission, thus avoiding
halo artefacts introduced by this specific effect. Probably
more important for image quality in PET-MRI is the
biodistribution of these tracers, specifically the accumu-
lation of radioactivity in the kidneys and the bladder. In
this context, recent investigations demonstrated promis-
ing results for [18F]PSMA-1007 [27] and [18F]YC-88
[28], showing comparatively low uptake in the kidneys.
These tracers might therefore be well suited for usage in
current clinical PET-MRI systems.
Conclusions
Halo artefacts around organs with high tracer uptake
such as kidneys and urinary bladder are frequent in
68Ga-PSMA PET-MRI and related to acquisition dur-
ation per bed position when using clinically available
scatter correction techniques. The use of emission data
to fill in missing information about parts of the arms in
the MR-derived attenuation maps seems to be an im-
portant mechanism for the occurrence of halo artefacts,
so that minimum acquisition times cannot be transferred
from PET-CT to PET-MRI. Acquisition times of 90 s per
bed position or less lead to a lower detectability of le-
sions, caused by image noise and halo artefacts, that
cannot be fully compensated by additional analysis of
non-scatter-corrected images.Acquisition times per bed position of at least 180 s are
therefore recommended when using MLAA and injected
tracer activities as in this study and a scan start one hour
after injection.
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